Stephen B Hanauer

List of Publications by Year
in descending order

Version: 2024-02-01

123 papers	30,372 citations	66234 42 h-index	25716 108 g-index
125 all docs	125 docs citations	125 times ranked	11816 citing authors

#	Article	IF	Citations
1	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohnâ€™s Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 578-590.e4.	2.4	94
2	Use of thiopurines in inflammatory bowel disease: an update. Intestinal Research, 2022, 20, 11-30.	1.0	38
3	Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflammatory Bowel Diseases, 2022, 28, 710-719.	0.9	24
4	Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. Journal of Clinical Psychology in Medical Settings, 2022, 29, 596-607.	0.8	12
5	Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflammatory Bowel Diseases, 2022, 28, 1012-1018.	0.9	8
6	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 28-37.	3.7	37
7	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. Journal of Crohn's and Colitis, 2022, 16, i379-i380.	0.6	1
8	DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohnâ€™s Disease in the SERENE studies. Journal of Crohn's and Colitis, 2022, 16, i124-i125.	0.6	3
9	P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohnâ€™s Disease and Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i434-i435.	0.6	0
10	Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflammatory Bowel Diseases, 2022, 28, 1603-1606.	0.9	3
11	A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2022, , .	1.4	1
12	Drug-Induced Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1759-1779.	2.4	20
13	Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohnâ€™s disease: a systematic review. Frontline Gastroenterology, 2021, 12, 423-436.	0.9	8
14	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn's and Colitis, 2021, 15, 1120-1129.	0.6	59
15	OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohnâ€™s Disease: The SEAVUE study. Journal of Crohn's and Colitis, 2021, 15, S001-S002.	0.6	23
16	Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease â€“ the Evolving Landscape. Current Gastroenterology Reports, 2021, 23, 16.	1.1	13
17	Which Diet for Crohnâ€™s Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond. Gastroenterology, 2021, 161, 798-800.	0.6	3
18	Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 816-825.	3.7	20

#	Article	IF	Citations
19	Review article: drugâ€induced small bowel injury. Alimentary Pharmacology and Therapeutics, 2021, 54, 1370-1388.	1.9	12
20	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
21	Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety) Tj ETQq1 1 0.784314 rgBT /O	1.1	14
22	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2020, 14, 23-32.	0.6	149
23	Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohnâ€™s Disease in the COVID Era. Crohn's & Colitis 360, 2020, 2, .	0.5	2
24	Executive Summary of â€˜Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United Statesâ€™. American Journal of Gastroenterology, 2020, 115, 1362-1366.	0.2	1
25	Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflammatory Bowel Diseases, 2020, 26, 1291-1305.	0.9	2
26	The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology, 2020, 72, 1127-1138.	3.6	29
27	Association between inflammatory bowel disease and prostate cancer: A largeâ€scale, prospective, populationâ€based study. International Journal of Cancer, 2020, 147, 2735-2742.	2.3	28
28	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. Journal of Crohn's and Colitis, 2020, 14, 1274-1281.	0.6	3
29	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. Journal of Crohn's and Colitis, 2020, 14, 1345-1353.	0.6	9
30	Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases, 2020, 26, 1808-1818.	0.9	16
31	Efficacy and Follow-up of Segmental or Subtotal Colectomy inÂPatients With Colitis-Associated Neoplasia. Clinical Gastroenterology and Hepatology, 2019, 17, 205-206.	2.4	21
32	One manâ€™s trash-another manâ€™s treasure: fecal transplantation. Hepatobiliary Surgery and Nutrition, 2019, 8, 623-625.	0.7	0
33	Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1525-1532.e1.	2.4	124
34	Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflammatory Bowel Diseases, 2019, 25, e114-e114.	0.9	0
35	P343 Efficacy of ustekinumab in Crohnâ€™s disease at maintenance Week 56: IM-UNITI study. Journal of Crohn's and Colitis, 2019, 13, S274-S274.	0.6	1
36	Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2019, 25, 1577-1585.	0.9	50

#	Article	IF	Citations
37	Too Soon to Discard 5-ASAs?. American Journal of Gastroenterology, 2019, 114, 534-535.	0.2	0
38	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 139-147.	2.4	138
39	More Than a Tumor Markerâ€¦A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1271-1276.	0.9	4
40	Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 2019, 75, 846-852.	0.9	47
41	Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseasesâ€"A Clinical Practice Update: Commentary. Gastroenterology, 2019, 156, 36-42.	0.6	39
42	Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.. Journal of Clinical Oncology, 2019, 37, 55-55.	0.8	0
43	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (<scp>AAA</scp> Study). Alimentary Pharmacology and Therapeutics, 2018, 47, 1092-1102.	1.9	38
44	A Never Ending STORI. Clinical Gastroenterology and Hepatology, 2018, 16, 1034-1036.	2.4	2
45	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 1660-1671.	0.6	175
46	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointestinal Endoscopy, 2018, 87, 1304-1309.	0.5	25
47	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohnâ€™s Disease: An International Multicenter Study. Inflammatory Bowel Diseases, 2018, 24, 2001-2006.	0.9	39
48	Longâ€term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 219-228.	1.9	35
49	Longâ€term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary Pharmacology and Therapeutics, 2018, 48, 65-77.	1.9	128
50	Inflammatory bowel disease and the risk of prostate cancer.. Journal of Clinical Oncology, 2018, 36, e17052-e17052.	0.8	0
51	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clinical Gastroenterology and Hepatology, 2017, 15, 1557-1564.e1.	2.4	157
52	Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2017, 15, 53-70.	0.3	11
53	Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. Lancet, The, 2017, 389, 1671-1672.	6.3	0
54	Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology, 2017, 10, 595-607.	1.3	27

#	Article	IF	Citations
55	Targeting Crohn's disease. Lancet, The, 2017, 390, 2742-2744.	6.3	0
56	Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010â€“2014. BMJ Open Gastroenterology, 2017, 4, e000155.	1.1	23
57	Vitamin D Levels and Outcomes in Inflammatory Bowel Diseaseâ€“Which is the Chicken and Which is the Egg?. Clinical Gastroenterology and Hepatology, 2017, 15, 247-248.	2.4	6
58	Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?. ACG Case Reports Journal, 2017, 4, e112.	0.2	35
59	Primary Adenocarcinoma of an Ileostomy in Crohn's Disease. ACG Case Reports Journal, 2016, 3, e112.	0.2	3
60	Oral or Topical 5-ASA in Ulcerative Colitis. Digestive Diseases, 2016, 34, 122-124.	0.8	12
61	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine, 2016, 374, 1754-1762.	13.9	361
62	Ustekinumab as Induction and Maintenance Therapy for Crohnâ€™s Disease. New England Journal of Medicine, 2016, 375, 1946-1960.	13.9	1,316
63	Hyperacute Methotrexate Pneumonitis in a Patient With Crohn'sÂDisease. Clinical Gastroenterology and Hepatology, 2016, 14, A29-A30.	2.4	5
64	Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Current Gastroenterology Reports, 2016, 18, 21.	1.1	13
65	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohnâ€™s Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578.	0.6	251
66	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology, 2016, 14, 348-354.e17.	2.4	309
67	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opinion on Drug Safety, 2015, 14, 1915-1934.	1.0	3
68	Heading Back to the Trough (Levels of Biologics in IBD). Clinical Gastroenterology and Hepatology, 2015, 13, 548-551.	2.4	7
69	ACG PRESIDENTIAL INTRODUCTION. American Journal of Gastroenterology, 2015, 110, 4-5.	0.2	1
70	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. Journal of Crohn's and Colitis, 2015, 9, 607-616.	0.6	50
71	The Holy Grail, or Only Half Way There?. Gastroenterology, 2015, 148, 8-10.	0.6	2
72	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2014, 12, 1981-1990.	2.4	24

#	Article	IF	Citations
73	Comment on â€˜Anti-Adhesion Therapies and the Rule of 3 for Rare Eventsâ€™. American Journal of Gastroenterology, 2014, 109, 1083-1084.	0.2	3
74	Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 927-935.	0.6	117
75	Effects of Vedolizumab Induction Therapy for Patients With Crohnâ€™s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology, 2014, 147, 618-627.e3.	0.6	607
76	Safety and Effectiveness of Long-term Allopurinolâ€“Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 363-369.	0.9	89
77	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2013, 369, 699-710.	13.9	2,114
78	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 2011, 60, 780-787.	6.1	750
79	Adalimumab sustains steroidâ€free remission after 3â€ƒyears of therapy for Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 306-317.	1.9	39
80	Positioning biologic agents in the treatment of CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 1570-1582.	0.9	13
81	Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 162-167.	0.6	63
82	Medical Management of Crohnâ€™s Disease: Treatment Algorithms 2009. Digestive Diseases, 2009, 27, 536-541.	0.8	10
83	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut, 2007, 56, 1232-1239.	6.1	866
84	Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. Gut, 2007, 56, 1181-1183.	6.1	44
85	Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. New England Journal of Medicine, 2007, 357, 239-250.	13.9	1,033
86	Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Annals of Internal Medicine, 2007, 146, 829.	2.0	849
87	Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine. Clinical Gastroenterology and Hepatology, 2007, 5, 209-214.	2.4	206
88	Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohnâ€™s Disease: The CHARM Trial. Gastroenterology, 2007, 132, 52-65.	0.6	1,986
89	Human Antiâ€“Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohnâ€™s Disease: the CLASSIC-I Trial. Gastroenterology, 2006, 130, 323-333.	0.6	1,523
90	Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases, 2006, 12, S3-S9.	0.9	756

#	Article	IF	Citations
91	Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Alimentary Pharmacology and Therapeutics, 2005, 22, 441-446.	1.9	202
92	Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial. American Journal of Gastroenterology, 2005, 100, 2478-2485.	0.2	286
93	Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2005, 353, 1912-1925.	13.9	880
94	Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2005, 353, 2462-2476.	13.9	3,500
95	Postoperative maintenance of Crohnâ€™s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology, 2004, 127, 723-729.	0.6	442
96	Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohnâ€™s disease. Clinical Gastroenterology and Hepatology, 2004, 2, 542-553.	2.4	582
97	COLAL-PRED Alizyme. Current Opinion in Investigational Drugs, 2004, 5, 1192-7.	2.3	7
98	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Reviews in Gastroenterological Disorders, 2004, 4 Suppl 3, S18-24.	0.6	13
99	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, The, 2002, 359, 1541-1549.	6.3	3,835
100	Crohn's disease therapy: step up or top down therapy. Acta Gastro-Enterologica Belgica, 2001, 64, 189-90.	0.4	0
101	Biologics in peri-operative management of Crohn's disease. Acta Gastro-Enterologica Belgica, 2001, 64, 191-2.	0.4	1
102	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. New England Journal of Medicine, 2000, 342, 1627-1632.	13.9	704
103	Nonobstructing Crohnâ€™s disease. Current Treatment Options in Gastroenterology, 1999, 2, 134-143.	0.3	0
104	Efficacy and safety of retreatment with antiâ€“tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology, 1999, 117, 761-769.	0.6	1,045
105	No Butts About It: Put the Fire Out By Lighting Up. Inflammatory Bowel Diseases, 1998, 4, 326.	0.9	1
106	Dose-Ranging Study of Mesalamine (PENTASA) Enemas in the Treatment of Acute Ulcerative Proctosigmoiditis: Results of a Multicentered Placebo-Controlled Trial. Inflammatory Bowel Diseases, 1998, 4, 79-83.	0.9	52
107	Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflammatory Bowel Diseases, 1998, 4, 79-83.	0.9	43
108	No butts about it: Put the fire oiut by lighting up. Inflammatory Bowel Diseases, 1998, 4, 326-326.	0.9	1

#	Article	IF	Citations
109	A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor Î± for Crohn's Disease. New England Journal of Medicine, 1997, 337, 1029-1036.	13.9	3,152
110	Nicotine in Ulcerative Colitis. BioDrugs, 1996, 5, 169-174.	0.7	23
111	Potential Human Models of Infammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 316-318.	1.8	0
112	THE MANAGEMENT OF ULCERATIVE COLITIS. Annual Review of Medicine, 1995, 46, 497-505.	5.0	16
113	New therapeutic approaches. Gastroenterology Clinics of North America, 1995, 24, 523-40.	1.0	1
114	Medical therapy of ulcerative colitis. Lancet, The, 1993, 342, 412-417.	6.3	62
115	Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. American Journal of Gastroenterology, 1993, 88, 646-9.	0.2	199
116	Olsalazine was more effective than mesalazine in maintaining remission from ulcerative colitis. ACP Journal Club, 1992, 117, 68.	0.1	0
117	Review: Most current drugs improve active Crohn disease but do not prevent relapse. ACP Journal Club, 1992, 117, 69.	0.1	0
118	Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease. Drug Safety, 1991, 6, 192-219.	1.4	65
119	The Role of Mesalazine in Crohn's Disease. Scandinavian Journal of Gastroenterology, 1990, 25, 56-59.	0.6	2
120	Inflammatory Bowel Disease Revisited: Newer Drugs. Scandinavian Journal of Gastroenterology, 1990, 25, 97-106.	0.6	14
121	Aminosalicylates: old and new. Mount Sinai Journal of Medicine, 1990, 57, 283-7.	1.9	1
122	5-ASA enema therapy. Netherlands Journal of Medicine, 1989, 35 Suppl 1, S11-20.	0.6	5
123	Clinical Experience with Tixocortol Pivalate. Canadian Journal of Gastroenterology & Hepatology, 1988, 2, 156-158.	1.8	7